Table 1 Characteristics of randomized controlled trials included
Source | Study Design | Participants characteristics | Population | Intervention (Drug, Dose, Frequency) | Control | Concomitant treatments | Duration | Follow-up | Outcomes* |
|---|---|---|---|---|---|---|---|---|---|
Barnes 2012 [11] | Multi-center, parallel-group, RCT | Steroid-free, moderate persistent asthma | 132 | OC000459, 200 mg, Twice daily | Placebo | SABA | 4 weeks | 10 weeks | ①⑤⑥⑦⑨⑪⑫⑯⑲ |
Pettipher 2014 [12] | Multi-center, parallel-group, RCT | Mild-to-moderate persistent steroid-free asthma | 482 | OC000459, 25 mg, Once daily | Placebo | SABA | 12 weeks | 20–22 weeks | ①⑤⑪⑯⑰⑱ |
OC000459, 200 mg, Once daily | |||||||||
OC000459, 100 mg, Twice daily | |||||||||
Singh 2013 [13] | Multi-center, two-period, cross-over, RCT | Steroid-naïve mild allergic asthma | 21 | OC000459, 200 mg, Twice daily | Placebo | SABA | 16 days | 35–41 days | ①③⑫â‘⑮⑯ |
Hall (trial 1) 2015 [14] | Multi-center, parallel-group, RCT | Symptomatic, mild-to-moderate, steroid-naïve asthma | 317 | BI 671800, 50 mg, Twice daily | Placebo | SABA | 6 weeks | 10 weeks | ③⑯⑰⑱⑲ |
BI 671800, 200 mg, Twice daily | |||||||||
BI 671800, 400 mg, Twice daily | |||||||||
Hall (trial 2) 2015 [14] | Symptomatic, mild-to-moderate asthmatic patients on ICS | 176 | BI 671800, 400 mg, Twice daily | Placebo | SABA, ICS | 10–12 weeks | ③⑯⑰⑱⑲ | ||
Bateman 2017 [16] | Multi-center, parallel-group, RCT | Allergic asthma inadequately controlled with low-dose ICS | 901 | Fevipiprant, 1 mg/3 mg/ 10 mg or 2 mg, Once daily or twice daily | placebo | SABA or ICS | 12 weeks | 22–24 weeks and 2 days | ⑪â‘⑯⑰⑱⑲ |
Fevipiprant, 30 mg/50 mg/ 75 mg or 25 mg, Once daily or twice daily | |||||||||
Fevipiprant, 150 mg/300 mg or 75 mg/ 150 mg, Once daily or twice daily | |||||||||
Fevipiprant, 450 mg, Once daily | |||||||||
Busse 2013 [17] | Multi-center, parallel-group, RCT | Inadequately controlled, moderate-to-severe asthma | 396 | AMG 853, 5 mg, Twice daily | Placebo | SABA, ICS | 12 weeks | 18 weeks | ①②③④⑤⑥⑧⑨⑩⑪⑫â‘⑯⑰⑱⑲ |
AMG 853, 25 mg, Twice daily | |||||||||
AMG 853, 100 mg, Twice daily | |||||||||
AMG 853, 200 mg, Twice daily | |||||||||
Erpenbeck 2016 [18] | Multi-center, parallel-group, RCT | mild-to-moderate persistent allergic asthma | 170 | Fevipiprant, 500 mg, Twice daily | Placebo | SABA | 4 weeks | 8 weeks | ⑧⑩⑯⑰ |
Fowler 2017 [19] | Single-center, parallel-group, RCT | Well controlled mild asthma | 84 | BI 1021958, 5/20/60/200 mg or 40/150/400 mg, Twice daily or once daily | Placebo | SABA | 15 days | 15 days | ⑯⑰⑱⑲ |
Gonem 2016 [20] | Single-center, parallel-group, RCT | Persistent, moderate-to-severe eosinophilic asthma | 61 | Fevipiprant, 225 mg, Twice daily | Placebo | SABA, ICS, LABA, or oral prednisone | 12 weeks | 20 weeks | ①②⑧⑨⑫⑬â‘⑯⑰ |
Kuna (trial 1) 2016 [21] | Multi-center, parallel-group, RCT | Stable asthma withdrawn from ICS | 113 | AZD1981, 1000 mg, Twice daily | Placebo | SABA | 4 weeks | 8 weeks | ①②⑤⑦⑥⑩⑫⑬â‘⑯⑰⑱⑲ |
Kuna (trial 2) 2016 [21] | Multi-center, parallel-group, RCT | Uncontrolled moderate-to-severe asthma despite moderate-to-high dose of ICS | 368 | AZD1981, 50 mg, Twice daily | Placebo | SABA, ICS | 4 weeks | 8 weeks | ①⑦⑯⑰⑱⑲ |
AZD1981, 400 mg, Twice daily | |||||||||
AZD1981, 1000 mg, Twice daily | |||||||||
Wenzel 2014 [22] | Multi-center, parallel-group, RCT | Steroid-free, mild atopic asthma | 184 | ARRY-502, 200 mg, Twice daily | Placebo | SABA | 4 weeks | 6 weeks | ①⑧⑨⑪⑯⑲ |
Bateman 2018 [23] | Multi-center, parallel-group, RCT | Persistent allergic asthma | 1144 | AZD1981, 80/200 mg, once daily, or 10/40/100 mg, twice daily | Placebo | ICS, LABA, SABA | 12 weeks | 15 weeks | ①⑧⑪⑯⑰⑱ |
Diamant 2014 [24] | Multi-center, two-period, cross-over, RCT | Stable, allergic asthma | 14 | Setipiprant, 1000 mg, Twice daily | Placebo | SABA | 5 days | 37 days | ⑬â‘â‘® |
Miller 2017 [25] | Multi-center, three-period, cross-over, RCT | Mild-to-moderate symptomatic asthma | 108 | BI 671800, 400 mg, Once daily (a.m) | Placebo | SABA, ICS | 12 weeks | 16–18 weeks | ③⑧⑯⑰⑱⑲ |